Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Hermann Luebbert Ph.D. | CEO, President & Executive Chairman | 656.01k | -- | 1956 |
| Mr. Eugene Frederick Leffler III | Chief Financial Officer | 338.71k | -- | 1985 |
| Ms. Erica F. Gates CPA, M.B.A. | Senior Director of Finance & Principal Accounting Officer | -- | -- | -- |
| Mr. Jon Lyons M.B.A., Ph.D. | Vice President of Scientific & Medical Affairs | -- | -- | -- |
| Ms. Alycia Torres | Vice President of Administration | -- | -- | -- |
| Mr. Daniel Hakansson J.D. | General Counsel & Head of Compliance | -- | -- | -- |
| Mr. Mark Baldyga | Vice President of Sales & Marketing | -- | -- | -- |
Biofrontera Inc.
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 83
Description
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Corporate Governance
Upcoming Events
March 13, 2025 at 8:00 PM UTC - March 17, 2025 at 8:00 PM UTC
Biofrontera Inc. Earnings Date
Recent Events
Recent Events Information Not Available